Phase II Study of Imatinib Mesylate as Adjuvant Treatment in High-Relapse Risk Localized Gastrointestinal Stromal Tumors With c-Kit Mutation

Trial Profile

Phase II Study of Imatinib Mesylate as Adjuvant Treatment in High-Relapse Risk Localized Gastrointestinal Stromal Tumors With c-Kit Mutation

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2015

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2013 Actual end date changed from Aug 2007 to Mar 2011 as reported by ClinicalTrials.gov.
    • 28 Nov 2007 Status changed from recruiting to completed.
    • 18 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top